2-氯-3-甲基苄基溴 | 134271-45-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氯-3-甲基苄基溴
• 英文名称: 2-chloro-3-methylbenzyl bromide
• 英文别名: 1-(Bromomethyl)-2-chloro-3-methylbenzene
• CAS: 134271-45-7
• 化学式: C₈H₈BrCl
• 分子量: 219.509
• InChiKey: MCEYVJFKCOFDCS-UHFFFAOYSA-N

物化性质

• 沸点：
  246.3±25.0 °C(Predicted)
• 密度：
  1.491±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  2-氯-3-甲基苄基溴 在 2-硝基丙烷 、 sodium ethanolate 作用下， 以 乙醇 为溶剂， 以77%的产率得到2-氯-3-甲基苯甲醛
  参考文献：
  名称：

  Synthesis of 9,10-dihydrosilaanthracenes with substituents ortho to the silicon and methylene bridges

  摘要：

  The generation of 9,10-dihydrosilaanthracenes with substituents on benzo ring carbons, specifically in the 4,5-positions adjacent to the methylene bridge, has been developed. Attempts to prepare the 1,8-isomer where the substituents are adjacent to the silicon bridge are also described. The diarylmethane precursors to the substituted 9,10-dihydrosilaanthracenes required the synthesis of 2,3-dihalotoluenes as well as isomeric 2,6-disubstituted benzaldehydes which were then condensed to diarylmethanols through the Grignard reagents. Ring closure to the 4,5-dimethyl-9,9-dialkyl-9,10-dihydro-9-silaanthracene, I, required the use of Rieke magnesium. The structure of I (alkyl = (i)Pr) was determined and demonstrates that the introduction of substituents adjacent to the methylene bridge causes the dihydrosilaanthracene framework to become nearly planar with a dihedral (or butterfly) angle of 170-degrees-C.

  DOI：

  10.1016/0022-328x(91)86224-e
• 作为产物：
  描述：

  2-氯-1,3-二甲苯 在 N-溴代丁二酰亚胺(NBS) 、 四氯化硅 作用下， 以 乙腈 为溶剂， 反应 10.0h， 以72%的产率得到2-氯-3-甲基苄基溴
  参考文献：
  名称：

  N-卤代琥珀酰亚胺/ SiCl 4是用于羰基化合物的α-单卤代反应和苄基卤代反应的常规，温和有效的系统

  摘要：

  N-卤代琥珀酰亚胺和四氯硅烷在乙腈中的组合被发现是有效的系统，用于选择性地羰基化合物的α-单卤代反应以及在温和条件下的苄基卤代反应。

  DOI：

  10.1016/j.tetlet.2011.05.135

文献信息

• IMIDAZOPIPERAZINONE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS
  申请人：Board of Regents, The University of Texas System

  公开号：US20190308978A1

  公开（公告）日：2019-10-10

  The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of transcription activating proteins such as CBP and P300 for the treatment or prevention of diseases such as proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases.

  本公开涉及可能用作转录激活蛋白如CBP和P300的抑制剂，用于治疗或预防诸如增殖性疾病、炎症性疾病、自身免疫疾病和纤维化疾病的异环化合物和方法。
• ARYL FLUOROETHYL UREAS ACTING AS ALPHA 2 ADRENERGIC AGENTS
  申请人：Chow Ken

  公开号：US20080194650A1

  公开（公告）日：2008-08-14

  The invention provides well-defined aryl fluoroethyl ureas that are useful as selective alpha 2 adrenergic agonists. As such, the compounds described herein are useful in treating a wide variety of disorders associated with modulation of alpha 2 adrenergic receptors.

  本发明提供明确定义的芳基氟代乙基脲，用作选择性的α2肾上腺素能激动剂。因此，所述化合物可用于治疗与α2肾上腺素能受体调节相关的一系列疾病。
• SUBSTITUTED URACILS AND USE THEREOF
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20160297771A1

  公开（公告）日：2016-10-13

  The present application relates to novel substituted uracil derivatives of formula (I), to a method for the production thereof, to the use thereof either alone or in combination for treating and/or preventing diseases, and to the use thereof for producing pharmaceuticals for the treatment and/or prevention of diseases.

  本申请涉及式(I)的新颖取代尿嘧啶衍生物，以及其生产方法，单独或结合使用于治疗和/或预防疾病，以及用于生产治疗和/或预防疾病的药物的用途。
• THERAPEUTIC FLUOROETHYLCYANO GUANIDINES
  申请人：Chow Ken

  公开号：US20080255230A1

  公开（公告）日：2008-10-16

  Disclosed herein is compound having a formula as described herein. Therapeutic methods, compositions, and medicaments related thereto are also disclosed.

  本文披露了具有如本文所述的化学式的化合物。还披露了与之相关的治疗方法、组成和药物。
• [EN] GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY<br/>[FR] COMPOSES MODULATEURS DE RECEPTEURS DE GLUCOCORTICOIDE ET PROCEDES
  申请人：LIGAND PHARM INC

  公开号：WO2005082909A1

  公开（公告）日：2005-09-09

  Provided herein are compounds of Formula (I) and pharmaceutically acceptable derivatives thereof. Certain of such compounds are selective glucocorticoid receptor modulators and/or selective glucocorticoid binding agents. Also provided are methods of making and using such compounds, including, but not limited to, using such compounds for treating various conditions.

  本文提供了式（I）的化合物及其药用可接受的衍生物。其中某些化合物是选择性糖皮质激素受体调节剂和/或选择性糖皮质激素结合剂。还提供了制备和使用这些化合物的方法，包括但不限于使用这些化合物治疗各种疾病。